NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

canis star, failure at mPFS maybe but not after 75% progressions (2/6/17 report) or after 70% secondary events (already expected 7/17). Upcoming publication of partially containing results contrary to what most expect, will most likely contain unblinded results because major elements of the trial (the small arm of 33 DCVAX-L untreated controls and all the PFS in the larger 298 patient trial group) contain respectively all DCVax-L untreated control or all trial patients. Results from these inherently unblended and unblinded subgroups will be more than sufficient to predict the success of the P3 trial. Results involving survival of patients with the different GBM biogroups (e.g. mesenchymal) may yield additional positive information. All IMHO.